Eliyahu Sharon Kalif - 28 Feb 2025 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
EVP, Chief Financial Officer
Signature
/s/ Dov Bergwerk as attorney-in-fact for Eliyahu Sharon Kalif
Issuer symbol
TEVA
Transactions as of
28 Feb 2025
Net transactions value
-$903,462
Form type
4
Filing time
04 Mar 2025, 16:02:49 UTC
Previous filing
30 Jan 2025
Next filing
06 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TEVA Ordinary Shares Sale $903,462 -55,750 -27% $16.21 147,941 28 Feb 2025 Direct F1, F2, F3
transaction TEVA Ordinary Shares Options Exercise +49,800 +34% 197,741 03 Mar 2025 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Options Exercise $0 -49,800 -33% $0.000000 99,602 03 Mar 2025 Ordinary Shares 49,800 Direct F1, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 29, 2024.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.16 to $16.23, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F5 Restricted share units were granted on March 3, 2023, with 49,800 vested on each of March 3, 2024 and March 3, 2025, 49,800 vesting on March 3, 2026, and 49,802 vesting on March 3, 2027.